Bacterial β-glucuronidase enzyme (GUS)

Bacterial β-glucuronidases are enzymes produced by a wide range of gut microbiota that catalyze the hydrolysis (“deglucuronidation”) of glucuronic acid from various substrates including dietary components, endogenous compounds, environmental chemicals, and many pharmaceuticals. These enzymes play a key role in reversing phase II liver metabolism—specifically glucuronic acid conjugation—by regenerating aglycone forms that can be reabsorbed through enterohepatic circulation. This process significantly affects drug pharmacokinetics and can lead to increased toxicity when toxic aglycones are released locally in the intestine. Structurally, bacterial β-glucuronidases belong to glycoside hydrolase family 2 with conserved folding motifs but exhibit diversity based on loop structures near their active sites which influence substrate specificity and localization within bacteria. Their activity is implicated both positively—in nutrient acquisition—and negatively—in promoting adverse drug reactions such as irinotecan-induced diarrhea or NSAID enteropathy. Selective inhibition is an area under investigation for improving therapeutic outcomes without broadly disrupting beneficial microbial functions.

Other names

Beta-glucuronidaseGUSBacterial GUSGlucuronidase (bacterial)uidA gene product (in bacteria)

Drugs targeting this enzyme typically act as β-glucuronidase inhibitors to prevent deglucuronidation, thereby reducing local toxicity or systemic reactivation. For example, selective inhibitors can block the conversion of inactive irinotecan metabolites back into their active/toxic forms within the gut, mitigating gastrointestinal side effects.